Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YSCH 01

Next Previous
Drug Profile

YSCH 01

Alternative Names: Recombinant L-IFN adenovirus - Shanghai Yuansong Biotechnology; YSCH-01

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Yuansong Biotechnology
  • Developer Huashan Hospital; Shanghai Yuansong Biotechnology
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants; Interferon stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Glioblastoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-0 development in Glioblastoma(Metastatic disease, Recurrent, Second-line therapy or greater) in China (Intratumoural, Injection)
  • 27 Nov 2025 Phase-0 for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (Inhalation) (NCT07793500)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (Intratumoural, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top